Skip to main content
. 2016 Jan 4;17(1):60. doi: 10.3390/ijms17010060

Figure 3.

Figure 3

Antiproliferative measurements of heterocyclic ruthenium(III) complexes graphs [2,3,4], parthenolide [D] in AC representing cell viability charts for the corresponding Ru(III) complexes against the selected cancer cell lines. (A) Human renal cancer cell (TK-10); (B) Human melanoma cancer cell (UACC-62); (C) Human breast cancer cell (MCF-7).